Hengrui Pharmaceuticals innovative drug SHR-A1811 was approved for clinical.

Guide: SHR-A1811 has good anti-tumor activity, safety, tolerance and pharmacokinetic characteristics.
recently, Hengrui Pharmaceuticals received the "Drug Clinical Trial Approval Notice" approved by the State Drug Administration, which approved the company's innovative drug injection SHR-A1811 for clinical trials for the treatment of advanced solid tumors expressed or mutated by HER2.
study found that human epidermal growth factor 2 (HER2) abnormalities exist in many tumors, including HER2 gene mutation, deletion, amplification and HER2 protein overexpression.
about 20% of breast cancers can be observed due to HER2 gene amplification and/or overexpression of HER2 signal activation, in other solid tumors such as gastric and gastroesophageal junction adenocarcinoma, bile duct cancer, colorectal cancer, non-small cell lung cancer, bladder cancer, etc. also have HER2 overexpression, the incidence ranges from 2% to 50%.
clinically HER2 expression is closely related to patient prognosis, such as her2 high expression of breast cancer immersion, disease-free survival is short, prognosis is poor.
in recent years, HER2 has become an ideal target for cancer immunobiological therapy, in the field of breast cancer, stomach cancer have anti-HER2 targeted drugs on the market.
injection with SHR-A1811 is the HER2-targeted antibody drug coupling (ADC), which can be combined with the cell membrane surface of her2 expression cells, and then the internal swallowing of cells to the lysosome to release small molecular toxins, and ultimately induce tumor cell apoptosis, both antibody highly targeted and the strong lethality of the cell toxic drug to the target cell.
preclinical results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, improve efficacy, meet clinical needs, for the vast number of tumor patients to provide more choices.
.